Zai Lab Limited (9688)

Overview

Zai Lab Limited is an innovative biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments aimed at addressing unmet medical needs in oncology, immunology, neuroscience, and infectious diseases. With a robust pipeline of commercial products and collaborations with major industry players, Zai Lab seeks to transform patient care and outcomes worldwide. Founded in 2013, and headquartered in Pudong, China, Zai Lab has quickly positioned itself at the forefront of the biopharmaceutical industry through strategic partnerships and a strong focus on research and development.

Products and Services

• Zejula: An orally administered inhibitor used in the treatment of ovarian cancer, highlighting the company's commitment to oncological health.
• VYVGART: A human IgG1 antibody fragment designed for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, demonstrating Zai Lab's entry into neurological and autoimmune disorders.
• NUZYRA: This product treats community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, reflecting Zai Lab's effort in combating infectious diseases.
• Optune: A novel therapy for glioblastoma multiforme, showcasing the company's innovative approach to treating cancer.
• Qinlock: Used for treating gastrointestinal stromal tumors, this product emphasizes the company's focus on targeted cancer therapies.
• Xacduro: A treatment developed for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, further representing Zai Lab's dedication to addressing critical infectious diseases.
• Augtyro: Focused on the treatment of ROS1 proto-oncogene 1 and non-small cell lung cancer, indicating Zai Lab's commitment to tailored oncological care.

Besides these commercial products, Zai Lab boasts a pipeline rich in promising developments across oncology, immunology, neuroscience, and infectious diseases. This includes therapies such as bemarituzumab, for oncology; efgartigimod, within immunology; and xanomeline and trospium chloride, in neuroscience. The company's extensive list of strategic collaborations, including those with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, and others, signifies its dynamic approach to innovation and dedication to advancing healthcare.